

November 08, 2022

National Stock Exchange of India Limited  
Exchange Plaza,  
Plot No. C/1, G Block,  
Bandra Kurla Complex, Bandra (E)  
Mumbai – 400 051

BSE Limited  
Corporate Relationship Department  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai – 400 001

**Subject: Press Release for Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Half Year ended September 30, 2022**

Dear Sir/Madam,

Please find enclosed herewith the Press Release for the unaudited Financial Results (Standalone and Consolidated) for the Quarter and Half Year ended September 30, 2022.

Thanking You,

Yours Faithfully,

**For Dr. Lal PathLabs Limited**

**Rajat Kalra**  
**Company Secretary and Legal Head**  
Encl.: As above

**Dr. Lal PathLabs Limited records revenue of Rs 534 Cr in Q2 FY 2022-23**

New Delhi, India, November 8, 2022 – Dr. Lal PathLabs Limited (referred to as the “Company”; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended September 30, 2022.

**Consolidated Performance Highlights: Q2 FY 2022-23 vs Q2 FY 2021-22**

- Non-Covid Revenue increased by 14.8% in Q2 FY23 to Rs. 514 Cr vs Rs 448 Cr in Q2 FY22
- Total Revenue increased by 7.1% in Q2 FY23 to Rs. 534 Cr vs Rs 498 Cr in Q2 FY22
- Covid and Allied contributed 3.7% to Revenue in Q2 FY23, 10.1% in Q2 FY22
- Normalised EBITDA (after adjustment for stock based compensation, CSR) for Q2 FY23 is at Rs. 150 Cr (margins 28.1%) Vs Rs 152 Cr in the same quarter last year
- Normalised PBT\* at Rs 117 Cr, margins 21.9% vs Rs 131 Cr. in Q2 last year
- Normalised PAT\* at Rs 86 Cr, margins 16.1% vs Rs 96 Cr. in Q2 last year

**Financial Overview (Consolidated) in Rs Cr**

Particulars	Q2			FH		
	FY23	FY22	Gr %	FY23	FY22	Gr %
<b>Revenue</b>	<b>533.8</b>	<b>498.4</b>	<b>7.1%</b>	<b>1036.5</b>	<b>1105.0</b>	<b>-6.2%</b>
<i>Non Covid</i>	514.2	447.9	14.8%	995.9	833.6	19.5%
<i>Covid &amp; Allied</i>	19.6	50.6	-61.3%	40.6	271.5	-85.0%
<b>Expenditure</b>	<b>390.0</b>	<b>357.0</b>	<b>9.3%</b>	<b>775.2</b>	<b>774.6</b>	<b>0.1%</b>
<b>EBITDA</b>	<b>143.8</b>	<b>141.5</b>	<b>1.6%</b>	<b>261.3</b>	<b>330.4</b>	<b>-20.9%</b>
<i>EBITDA Margins</i>	26.9%	28.4%		25.2%	29.9%	
RSU & CSR cost	6.3	10.7		14.3	20.8	
<b>Normalised EBITDA</b>	<b>150.1</b>	<b>152.2</b>	<b>-1.4%</b>	<b>275.6</b>	<b>351.2</b>	<b>-21.5%</b>
<i>EBITDA Margins</i>	28.1%	30.5%		26.6%	31.8%	
Net other Income/(Interest)	-2.2	9.7		-2.4	19.1	
Depreciation Cost	38.8	20.5		74.7	39.7	
<b>PBT</b>	<b>102.8</b>	<b>130.6</b>	<b>-21.3%</b>	<b>184.2</b>	<b>309.9</b>	<b>-40.6%</b>
<i>Margins</i>	19.3%	26.2%		17.8%	28.0%	
<b>PAT</b>	<b>72.4</b>	<b>96.3</b>	<b>-24.8%</b>	<b>130.6</b>	<b>230.0</b>	<b>-43.2%</b>
<i>Margins</i>	13.6%	19.3%		12.6%	20.8%	
<b>EPS</b>	<b>8.6</b>	<b>11.5</b>	<b>-24.8%</b>	<b>15.6</b>	<b>27.4</b>	<b>-43.0%</b>
<b>Normalised PBT*</b>	<b>117.0</b>	<b>130.6</b>	<b>-10.4%</b>	<b>210.6</b>	<b>309.9</b>	<b>-32.0%</b>
<i>Margins</i>	21.9%	26.2%		20.3%	28.0%	
<b>Normalised PAT*</b>	<b>86.2</b>	<b>96.3</b>	<b>-10.5%</b>	<b>156.6</b>	<b>230.0</b>	<b>-31.9%</b>
<i>Margins</i>	16.1%	19.3%		15.1%	20.8%	

\*Normalised PBT and PAT are excluding notional depreciation and exceptional expenses of Rs.14 Cr in Q2'23 and Rs. 26 Cr in FH'23



## About Dr. Lal PathLabs Limited

---

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its' integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

As on March 31, 2022 the company has 277 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab at Kolkata & Bangalore), 4,731 Patient Service Centers (PSCs) and 10,599 Pick-up Points (PUPs). Its' customers include individual patients, hospitals and other healthcare providers and corporate customers.

## Contact Details

---

Ved Goel  
Group Chief Financial Officer  
*Dr. Lal PathLabs Limited*

+91 124 3016500  
[cfo@lalpathlabs.com](mailto:cfo@lalpathlabs.com)

Rakshit Tewari/Gargi Mukherjee  
*Adfactors PR*

+91 9935551036/+91 9650944756  
[rakshit.tewari@adfactorspr.com](mailto:rakshit.tewari@adfactorspr.com)  
[gargi.mukherjee@adfactorspr.com](mailto:gargi.mukherjee@adfactorspr.com)

For further information on Dr. Lal PathLabs see [www.lalpathlabs.com](http://www.lalpathlabs.com)

---

## Safe Harbour

---

This release contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr. Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr. Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.